ARA-290 (Cibinetide): What It Is, How It Works & What the Research Shows (Explained Simply)

Use code PEPHUB at Petratide Science, True Amino Labs, Blue Ridge Peptides!

Look, I need to clear something up first.

A lot of people hear "ARA-290 is made from EPO" and think "oh, so it's basically baby EPO, right? The blood doping stuff?"

Nope. Not even close.

ARA-290 comes from the EPO molecule, but it was built on purpose to skip the part of EPO that makes red blood cells. In the research, it does not raise red blood cell counts. That's literally the whole point of it.

And here's what makes ARA-290 different from almost every other peptide we cover on this site: it has real, randomized, placebo-controlled human trials. Not just mice. Not just a cell in a dish. Actual Phase 2 trials, run at real universities, published in peer-reviewed journals.

But "has human trials" and "is proven" are two very different things. This post breaks down what ARA-290 is, how it works, every major study it's been in, and where the data runs out. No fluff, just the research explained in plain English.

Quick Answers

What is ARA-290? An 11-amino-acid peptide cut from the EPO hormone, designed to turn on EPO's tissue-protection signal without making red blood cells. It's also called cibinetide.

Has it been studied in humans? Yes. Phase 2 trials in sarcoidosis-related nerve damage, painful nerve damage in type 2 diabetes, and diabetic eye swelling.

What's the strongest finding? In a 64-person trial, the 4 mg group grew back measurable nerve fiber area in the eye compared to placebo after 28 days (P = 0.012).

Did it reduce pain? Mixed. Smaller early trials said yes. In the biggest trial, pain dropped in every group — including placebo — and the difference wasn't statistically significant.

Is it approved? No. It got orphan drug status in the U.S. and EU, but no Phase 3 trial was ever completed, and it isn't approved for any use anywhere.

What Is ARA-290, Really?

To get ARA-290, you have to get EPO first.

EPO (short for erythropoietin) is a hormone your body already makes. Its main job is telling your bone marrow to make red blood cells. That's also why it became infamous in endurance sports doping — more red blood cells means more oxygen.

But researchers noticed EPO did something else in lab studies. It seemed to protect stressed and injured tissue — nerves, kidneys, the heart.

The problem? You can't give someone big doses of EPO to protect tissue without also cranking up red blood cell production. That thickens the blood and raises the risk of clots. In fact, clinical trials of high-dose EPO after kidney transplants showed no short-term benefit and a possible increase in clotting events.

So scientists went looking for a way to keep the "protect" part and lose the "make blood" part. ARA-290 is what they came up with. It's just 11 amino acids long, cut from a section of the EPO molecule called helix B. You'll also see it called cibinetide or pHBSP (pyroglutamate helix-B surface peptide) in the research.

Think of EPO like a master key that opens two doors. ARA-290 is a copy of that key cut to fit only one of them.

How Does ARA-290 Actually Work? (The Mechanism, Explained Simply)

This is where it gets interesting.

EPO has two different "docking stations" on cells:

• The blood door: Two standard EPO receptors paired together. This is the one that tells your body to make red blood cells.
• The repair door: One EPO receptor paired with a different partner called the beta-common receptor (CD131). Researchers Michael Brines and Anthony Cerami named this the innate repair receptor. (Fun fact: Cerami is the scientist who developed the HbA1c test used in diabetes care.)

ARA-290 was engineered to fit the repair door and ignore the blood door.

Here's the simple version of what happens next:

1. When tissue gets hurt or stressed, cells put up more of these repair doors. Healthy, calm tissue doesn't have many.
2. ARA-290 locks onto those repair doors.
3. That flips on the cell's protection and repair programs.
4. At the same time, it turns down an inflammation "alarm switch" called NF-κB inside immune cells.
5. In nerve injury studies, it also calmed down microglia — the immune cells of the nervous system that drive long-term nerve pain.

So instead of flooding the whole body with a signal, ARA-290 mostly acts where the damage is, because that's where the repair doors show up. Kind of elegant, honestly.

How do we know it actually uses that repair door? Scientists tested it in mice bred without the beta-common receptor. If ARA-290 needed that receptor, it should stop working in those mice.

It did stop working. The pain relief seen in normal mice disappeared. The same thing happened in immune cell studies — no CD131, no anti-inflammatory effect.

One honest footnote: not everyone agrees on exactly how the repair door is built. A 2018 study tested whether the EPO receptor and the beta-common receptor physically stick together, and it found no direct contact between their outer sections — with or without ARA-290 there. That doesn't erase the trial results, but it means the "how" is still being argued about.

What Has ARA-290 Been Studied For? (Every Human Trial)

Most of the human research came out of Leiden University Medical Center in the Netherlands, plus a larger trial led by Cleveland Clinic sarcoidosis researchers and an eye trial at Queen's University Belfast in Northern Ireland.

Here's every major human trial at a glance:

Sarcoidosis Nerve Damage (The Main Story)

Sarcoidosis is an inflammatory disease, and a lot of people with it develop small fiber neuropathy — damage to the tiny nerves that carry pain, temperature, and automatic body signals. It causes burning, tingling, and numbness, usually starting in the feet. Treatment options are mostly about managing symptoms, not fixing the nerves.

That's why it became ARA-290's lead target.

The 2012 pilot: The first randomized trial enrolled 22 sarcoidosis patients. ARA-290 was given by IV three times a week for four weeks. The ARA-290 group improved more than placebo on the Small Fiber Neuropathy Screening List, and no safety concerns came up.

The 2013 follow-up: This one switched to a daily injection under the skin for 28 days. Researchers reported:

• A significant increase in corneal small nerve fiber density
• Changes in skin temperature sensitivity
• Better exercise capacity on the 6-minute walk test
• Symptom improvements that held through follow-up

One honesty note: in 2016 the authors published a correction. An arithmetic error in their software meant the corneal nerve fiber area numbers in this paper were reported too small. It doesn't flip the findings, but it's the kind of detail most peptide sites never mention.

Wait — why are they measuring nerves in the eye? Your cornea (the clear front of your eye) is packed with tiny nerve fibers. A special microscope can photograph them without cutting anything. That makes it one of the best ways to measure small nerve damage — and regrowth.

DOSARA — The Biggest Trial

This is the one that matters most. Published in 2017, it enrolled 64 people with sarcoidosis-related nerve loss and nerve pain. It tested three daily doses — 1, 4, and 8 mg — against placebo for 28 days.

What happened:

• The 4 mg group showed a significant increase in corneal nerve fiber area vs. placebo (P = 0.012).
• Regrowing nerve fibers in the skin also went up in the 4 mg group (P = 0.035).
• The 1 mg and 8 mg groups did not hit significance on the main nerve measure. More wasn't better.
• Pain improved in every group — including placebo. The extra pain drop in the 4 mg group wasn't statistically significant (P = 0.157).

Translation: the strongest result is structural. The nerve fibers appeared to grow back. The pain relief people hype online didn't clearly beat placebo in the biggest trial.

Type 2 Diabetes & Nerve Pain

This is the study that started the "ARA-290 for blood sugar" buzz. Researchers ran a double-blind, placebo-controlled trial in people with type 2 diabetes and painful nerve damage. Participants got ARA-290 or placebo daily for 28 days, then were followed for another month.

Results:

• HbA1c and cholesterol/lipid numbers improved in the ARA-290 group across the full 56 days
• Nerve pain symptoms improved significantly on a standard pain questionnaire
• Corneal nerve density went up — and in people who started with the most nerve loss, symptom improvement tracked with how much their corneal nerves recovered. That link didn't show up in the placebo group.

Sounds great. But this was a small, short, exploratory trial. It wasn't built to prove a blood sugar effect. Treat it as a signal worth testing, not a finding.

Diabetic Eye Swelling

Researchers at Queen's University Belfast tested whether 12 weeks of daily ARA-290 could help diabetic macular edema — fluid buildup in the back of the eye that blurs central vision. It was a small pilot with no placebo group. Nine patients enrolled and eight finished.

The researchers concluded the 12-week course was safe. No serious side effects, and nobody developed antibodies against the peptide. Some participants improved on retinal thickness, tear production, blood sugar, and kidney markers — but with eight people and no comparison group, that's a reason to study it more, not proof it works for eye disease.

The Animal & Lab Research

Before the human trials, ARA-290 was tested in a wide range of injury models. This is where a lot of the "it fixes everything" hype comes from — so remember, none of these have been confirmed in people.

• Nerve pain (rats and mice): Fast, long-lasting relief of touch and cold pain sensitivity after nerve injury, plus calmer spinal microglia.
• Gut inflammation (mice): In chemically induced colitis, ARA-290 improved the disease course, weight gain, and survival, with fewer invading immune cells.
• Bone (mice): One month of treatment raised bone density about 5–6% and cut the formation of bone-breaking cells.
• Kidney (pigs, rats, mice): After cutting off and restoring blood flow to the kidney, ARA-290 improved kidney filtration and reduced inflammation and scarring. The pig study matters because pig kidneys are much closer to human kidneys.
• Diabetic nerves (mice): Reversed diabetes-related damage to the body's automatic nerves.
• Skin wounds (rats): Smaller wounds and faster healing in punch-biopsy, pressure-ulcer, and diabetic wound models.
• Brain injury (rats): Better performance on a memory maze after traumatic brain injury.

The Honest Gap: What We Still Don't Know

ARA-290 has more human data than most research peptides. That's genuinely rare. But here's what the research doesn't show yet:

• Every human trial was small and short. The biggest had 64 people. Most ran 28 days. The longest was 12 weeks — in just 8 people.
• The best result is a stand-in marker. Nerve fiber area in the eye is a real sign of regrowth, but it isn't the same as proven, lasting pain relief.
• Pain relief didn't clearly beat placebo in the biggest trial.
• The dose results were weird. Only 4 mg hit significance. 8 mg didn't.
• The blood sugar data comes from one small exploratory trial.
• Nobody has published how ARA-290 behaves in the human body — how long it lasts in the blood or how much gets absorbed.
• No long-term safety data. Nobody has studied months or years of exposure.
• The immune trade-off is untested. ARA-290 calms innate immune cells — the same cells that fight bacteria. No study has checked whether that affects infection response.
• Results come from specific diseases. Sarcoidosis and diabetic nerve damage. Stretching that to "general recovery" is a leap the data doesn't make.

Any source calling ARA-290 a "proven" nerve repair or recovery peptide is getting ahead of the science. The honest summary: real human signal, a clever mechanism, and a development program that never finished the job.

Is ARA-290 Legal? Where Can You Even Get It?

This varies by jurisdiction and changes, so treat this as a general picture, not legal advice.

• United States: ARA-290 is sold as a "research use only" chemical — not approved as a medicine for human use. It did earn orphan drug designation and fast track status from U.S. regulators for sarcoidosis-related small fiber neuropathy. But here's the nuance that matters: those designations are about speeding up development. They are not approval. The developer, Araim Pharmaceuticals, completed an end-of-Phase-2 meeting and a 2014 review said Phase 3 was planned — but that Phase 3 never happened, and the company has reportedly closed its doors.
• European Union: ARA-290 also received EU orphan designation for the same condition. Same deal — a designation, not an approval.
• Everywhere else: Like most unapproved peptides, it falls into a "research chemical" category, with each country setting its own import and prescription rules.
• Competitive sports: This one's clear. The World Anti-Doping Agency's Prohibited List bans innate repair receptor agonists at all times, in and out of competition — and earlier versions of the list named ARA-290 directly as an example. Athletes subject to testing should not be anywhere near this one.

Bottom line: everywhere ARA-290 is sold, it's sold for research purposes only, not for human use. That label reflects the actual state of the science — a promising Phase 2 story that never got its Phase 3 answer.

Safety: What We Know So Far

ARA-290 has a favorable safety record in the human research conducted so far:

• Across the trials, reported side effects were generally mild and similar to placebo.
• In the 12-week eye trial, there were no serious adverse events and no anti-drug antibodies.
• Because it's built to skip the blood door, the trials did not report the red blood cell increases that make EPO risky.

That said:

• Long-term human safety data doesn't exist, because long-term human studies haven't been done.
• Every trial was small, which means rare side effects wouldn't show up.
• The material sold today is not the pharmaceutical-grade product used in the trials.

Researchers sourcing ARA-290 should always check the Certificate of Analysis first — my COA Guide walks through exactly what to look for. And when reconstituting a lyophilized vial, the Free Reconstitution Calculator handles the calculation.

My Honest Take

ARA-290 is one of the more legit compounds in the research peptide world. It came out of serious academic labs. It was built around a genuinely clever idea — keep EPO's protective signal, ditch the blood-thickening job. And it made it through multiple randomized, placebo-controlled human trials, which most peptides people talk about online never get close to.

But I'd push back on how it's getting marketed right now. The best evidence says ARA-290 may help small nerve fibers regrow in sarcoidosis-related nerve damage. That's a specific, narrow, and honestly really interesting finding. It is not proof of pain relief, blood sugar control, gut repair, or general "recovery."

The human data is there — it's just small, short, and unfinished. That's not a red flag, that's just where the science stands, stated plainly rather than overstated. If anyone ever revives the Phase 3 program, that's the study that would actually answer the big question.

Frequently Asked Questions About ARA-290

Researching ARA-290? Save With Code PEPHUB

Research Pep Hub is education first — we don't sell peptides, and we don't rank vendors. Use code PEPHUB at any of these partners. Pick the one that fits your research and always check the COA.

• Petratide Science
• True Amino Labs
• Blue Ridge Peptides

Research Sources

Human clinical trials

• Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine, 2012. PMID 23168581.
• Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine, 2013. (2016 correction)
• Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine, 2015.
• Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Investigative Ophthalmology & Visual Science, 2017.
• Lois N, et al. A Phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema. Journal of Clinical Medicine, 2020.

Trial registrations

• NCT02039687 — DOSARA Phase 2b in sarcoidosis
• ISRCTN16962255 — Phase 2 in diabetic macular edema
• NTR3858 — Netherlands Trial Register, type 2 diabetes trial

Reviews and mechanism

• Dahan A, et al. Targeting the innate repair receptor to treat neuropathy. PAIN Reports, 2016.
• van Velzen M, et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opinion on Investigational Drugs, 2014.
• Cheung Tung Shing KS, et al. EPO does not promote interaction between the erythropoietin and beta-common receptors. Scientific Reports, 2018.

Animal and lab studies

• Nairz M, et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific Reports, 2017.
• Awida Z, et al. The non-erythropoietic EPO analogue cibinetide inhibits osteoclastogenesis in vitro and increases bone mineral density in mice. International Journal of Molecular Sciences, 2022.
• ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury (pig model)
• Renoprotective capacities of non-erythropoietic EPO derivative, ARA290 (rat model)
• Swartjes M, et al. ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular Pain, 2014.

Sports

• World Anti-Doping Agency Prohibited List, section S2: innate repair receptor agonists.

These compounds are supplied strictly for laboratory research and are not approved for human or veterinary use. Nothing on this site is medical advice or an instruction for use in humans. I'm an affiliate for vendors linked and may earn commissions from purchases.

Tags: ARA-290, cibinetide, innate repair receptor, EPO, small fiber neuropathy, sarcoidosis, nerve repair, anti-inflammatory